-
Mashup Score: 0Immune Checkpoint Inhibitors for Patients With Child-Pugh Class B vs A Advanced Hepatocellular Carcinoma - The ASCO Post - 8 month(s) ago
By Matthew Stenger Posted: 9/7/2023 10:30:00 AM Last Updated: 9/7/2023 11:17:33 AM In a systematic review and meta-analysis reported in JAMA Oncology, Xie et al explored outcomes associated with immune checkpoint inhibition among patients with advanced hepatocellular carcinoma with Child-Pugh B vs Child-Pugh…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
MicroRNA-22 produced better liver cancer survival outcomes than current FDA-approved drug in mouse study.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Hepatobiliary - Researchers Identify Alterations in Ammonia Metabolic Pathways in Fibrolamellar Liver Cancer - 8 month(s) ago
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Personalized Calculator May Be Predictive of Benefits From Adjuvant TACE in Patients With Hepatocellular Carcinoma Undergoing Hepatectomy - The ASCO Post - 8 month(s) ago
By The ASCO Post Staff Posted: 8/23/2023 10:38:00 AM Last Updated: 8/23/2023 9:46:12 AM Researchers have developed a personalized calculator that may be capable of predicting the reduced risk of early recurrence in patients with hepatocellular carcinoma, according to a recent study published by Chen et al in…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Personalized Neoantigen Vaccine Induces Continued Responses in Pretreated, Advanced HCC - 8 month(s) ago
Intradermal injection with GNOS-PV02 plus plasmid-encoded interleukin-12 followed by electroporation elicited complete molecular response detected via circulating tumor DNA in 4 additional patients as second-line therapy in patients with advanced hepatocellular carcinoma.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0SCG101: a novel T-cell therapy in advanced hepatitis B-related HCC - 9 month(s) ago
Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, discusses an ongoing Phase I trial (NCT05417932) evaluating the safety and efficacy of autologous SCG101 T cell therapy in patients with advanced hepatitis B-related hepatocellular carcinoma (HCC). The primary endpoints of the trial include safety, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D). Secondary endpoints include objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and changes in serum HBsAg levels. The trial is actively enrolling, with the Phase II portion expected to commence by the second half of 2023. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2JNCCN 360 - Hepatobiliary - Researchers Use Genomics to Inform the Creation of New Model for Pediatric Hepatoblastoma - 9 month(s) ago
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Hepatobiliary - Using M7G-Linked Long Noncoding RNAs to Predict Outcomes in Hepatocellular Carcinoma - 9 month(s) ago
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Phase 3 Findings Show PFS Benefit With Frontline Rivoceranib Plus Camrelizumab in Patients With Unresectable HCC - 9 month(s) ago
Patients with unresectable hepatocellular carcinoma who received rivoceranib/camrelizumab achieved a median progression-free survival of 5.6 months vs 3.7 months with sorafenib.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Does Daily Consumption of Sugar-Sweetened Beverages Increase the Risk of Liver Disease Among Postmenopausal Women - The ASCO Post - 9 month(s) ago
Approximately 65% of adults in the United States consume sugar-sweetened beverages daily. Researchers led a study examining the associations among intake of sugar-sweetened or artificially sweetened beverages and the incidence of liver cancer and chronic liver disease mortality in a large cohort of postmenopausal women. Findings were published by Zhao et al in JAMA. “To our knowledge, this is the first study to report an association between sugar-sweetened beverage intake and chronic liver disease
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Immune Checkpoint Inhibitors for Patients With Child-Pugh Class B vs A Advanced Hepatocellular Carcinoma https://t.co/QSXuRmWfhk #immunotherapy #hpbcsm #HCC #livercancer #oncology